Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;24(10):1836-1847.
doi: 10.1038/mt.2016.126. Epub 2016 Jun 27.

Exosome-mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA Silencing

Marie-Cécile Didiot  1   2 , Lauren M Hall  1   3 , Andrew H Coles  1   2 , Reka A Haraszti  1   2 , Bruno Mdc Godinho  1   2 , Kathryn Chase  1   3 , Ellen Sapp  4 , Socheata Ly  1   2 , Julia F Alterman  1   2 , Matthew R Hassler  1   2 , Dimas Echeverria  1   2 , Lakshmi Raj  5 , David V Morrissey  5 , Marian DiFiglia  4 , Neil Aronin  1   3 , Anastasia Khvorova  1   2
Affiliations

Exosome-mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA Silencing

Marie-Cécile Didiot et al. Mol Ther. 2016 Oct.

Abstract

Delivery represents a significant barrier to the clinical advancement of oligonucleotide therapeutics for the treatment of neurological disorders, such as Huntington's disease. Small, endogenous vesicles known as exosomes have the potential to act as oligonucleotide delivery vehicles, but robust and scalable methods for loading RNA therapeutic cargo into exosomes are lacking. Here, we show that hydrophobically modified small interfering RNAs (hsiRNAs) efficiently load into exosomes upon co-incubation, without altering vesicle size distribution or integrity. Exosomes loaded with hsiRNAs targeting Huntingtin mRNA were efficiently internalized by mouse primary cortical neurons and promoted dose-dependent silencing of Huntingtin mRNA and protein. Unilateral infusion of hsiRNA-loaded exosomes, but not hsiRNAs alone, into mouse striatum resulted in bilateral oligonucleotide distribution and statistically significant bilateral silencing of up to 35% of Huntingtin mRNA. The broad distribution and efficacy of hsiRNA-loaded exosomes delivered to brain is expected to advance the development of therapies for the treatment of Huntington's disease and other neurodegenerative disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Efficient loading of exosomes with hsiRNAs. (a) hsiRNAHTT schematic and PyMOL model. (b) Flowchart of exosome loading procedure: co-incubation of Cy3-hsiRNA and exosomes results in Cy3-hsiRNA-loaded exosomes that pellet by ultracentrifugation. (c) Bar graphs showing the percent of Cy3-hsiRNA or Cy3-hsiRNA-exosomes in the pellet (black) and supernatant (white) after ultracentrifugation (n = 3; mean ± SD). (d) hsiRNA loading does not affect exosome size distribution (nonloaded exosomes, solid line; hsiRNA-loaded exosomes, dashed line). (e) Electron microscopy of exosomes in the absence (left) or presence (right) of hsiRNA. Exosomes remain intact when loaded with hsiRNA (scale bar = 100 nm). hsiRNA, hydrophobically modified small interfering RNA.
Figure 2
Figure 2
Internalization of hydrophobic Cy3-hsiRNA-loaded exosomes by primary cortical neurons. (a) Kinetics of Cy3-hsiRNAHTT-loaded exosomes shows significant co-localization between exosomes and hsiRNAs. hsiRNAHTT labeled with Cy3 (red); exosomes labeled with PKH67 (green); nuclei labeled with Hoechst (blue). Samples were visualized at 63× magnification. Scale bar = 10 µm. Arrows show hisRNAHTT-exosomes. (b) Bar graphs showing the absolute quantification of Cy3-fluorescence in cells upon incubation with Cy3-hsiRNA (black) or Cy3-hsiRNA-exosomes (white) (n = 5; mean ± SD; *P < 0.05, **P < 0.01, paired t-test comparing the Cy3 intensity of hsiRNA nonloaded versus loaded in exosomes). (c) Quantification of Cy3-hsiRNAHTT taken up by primary neurons with increasing amounts of Cy3-hsiRNAHTT-loaded exosomes. The level of Cy3-labeled hsiRNAs was measured by high-performance liquid chromatography (n = 3 technical replicates; mean ± SD). hsiRNA, hydrophobically modified small interfering RNA.
Figure 3
Figure 3
Concentration-dependent silencing of Huntingtin mRNA and protein by hsiRNAHTT-loaded exosomes in primary cortical neurons. (a) Graph of Htt mRNA levels in cells treated with increasing amounts of hsiRNAHTT-loaded exosomes (solid line), hsiRNANTC-loaded exosomes (dotted line), or nonloaded exosomes (dashed line) for 7 days. Htt mRNA levels are normalized to Ppib mRNA (housekeeping control) and presented as percent of untreated control (n = 4 biological replicates, each performed with n = 3 technical replicates; mean ± SD; *P < 0.05, **P < 0.01, paired t-test comparing each concentration to hsiRNANTC-loaded exosomes). (b) Graph of HTT protein levels in cells treated with increasing amounts of hsiRNAHTT-loaded exosomes (solid line; n = 5 biological replicates) or hsiRNANTC-loaded exosomes (dotted line; n = 3 biological replicates) for 7 days. HTT signal was normalized to Tubulin. Data at each concentration are presented as percent of untreated control samples (mean ± SD; *P < 0.05, **P < 0.01, paired t-test comparing each concentration to untreated samples). hsiRNA, hydrophobically modified small interfering RNA; NTC, nontargeting control.
Figure 4
Figure 4
Exosomes promote bilateral distribution of hsiRNAs. (a,b) Images of ipsilateral (left) and contralateral (right) brain sections after infusion of Cy3-hsiRNAHTT-loaded exosomes (red) (a) or unlabeled hsiRNAHTT-loaded exosomes (b). Nuclei stained with Hoechst (blue). Samples were visualized at 2.5× magnification. Scale bar = 1 mm. All pictures were acquired with the same microscope settings. (c,d) Plot showing tissue concentrations of hsiRNAHTT (c) or hsiRNAsFlt1 (d) guide strands measured by peptide nucleic acid hybridization in biopsies from the ipsilateral (IL) and contralateral (CL) striata of mice treated with hsiRNA-loaded exosomes, hsiRNAs alone, or artificial cerebrospinal fluid (CSF) (hsiRNAHTT, n = 7 mice per group; hsiRNAsFlt1, n = 9 mice per group). Each point in the plot represents the level of hsiRNA guide strands in an individual mouse, and the mean ± SD of each group is indicated. Data were analyzed using a nonparametric Kruskal–Wallis test, and the mean of each column was compared to the mean of the corresponding artificial CSF control column. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. hsiRNA, hydrophobically modified small interfering RNA.
Figure 5
Figure 5
hsiRNAHTT-loaded exosomes induce bilateral Htt mRNA silencing in vivo in mouse brain. (a) Plots showing Htt mRNA levels in biopsies from the ipsilateral (closed) and contralateral (open) striata of mice treated with artificial cerebrospinal fluid (CSF), unloaded exosomes, hsiRNANTC-loaded exosomes, 0.5 and 1 µg/day hsiRNAHTT, or 0.5 and 1 µg/day hsiRNAHTT-loaded exosomes (red). Exosomes were delivered at 2–4 × 1010 particles/day. Level of Htt mRNA was normalized to Ppib mRNA (housekeeping control), and data are presented as percent of untreated control (n = 6–10 mice per group). Each point represents the averaged level of Htt mRNA from three biopsies of an individual mouse, and the mean ± SD of each group is indicated. (b) Bonferroni's multiple comparison tests between groups treated with artificial CSF, exosomes, hsiRNAHTT, or hsiRNAHTT-exosomes and group treated with hsiRNANTC-loaded exosomes. IL, ipsilateral; CL, contralateral; hsiRNA, hydrophobically modified small interfering RNA; NTC, nontargeting control.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. HD Consortium (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971–983. - PubMed
    1. Ross, CA and Tabrizi, SJ (2011). Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10: 83–98. - PubMed
    1. Warby, SC, Graham, RK and Hayden, MR (2010). Huntington Disease. GeneReviewsTM. <http://www.ncbi.nlm.nih.gov/books/NBK1305/>.
    1. Boudreau, RL, McBride, JL, Martins, I, Shen, S, Xing, Y, Carter, BJ et al. (2009). Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther 17: 1053–1063. - PMC - PubMed
    1. Kordasiewicz, HB, Stanek, LM, Wancewicz, EV, Mazur, C, McAlonis, MM, Pytel, KA et al. (2012). Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74: 1031–1044. - PMC - PubMed

Publication types